Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

NCT06145633 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Castration-Resistant Prostate Carcinoma
Metastatic Prostate Adenocarcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions

PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Scan
PROCEDURE: Computed Tomography
OTHER: Fludeoxyglucose F-18
OTHER: Gallium Ga 68 Gozetotide
DRUG: Lutetium Lu 177 Vipivotide Tetraxetan
PROCEDURE: Positron Emission Tomography
PROCEDURE: Single Photon Emission Computed Tomography
DRUG: Vorinostat

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]